Metropolitan General Hospital | Oncology Clinic - Clinical Trials and Research Clinic

Research site

(Unclaimed)

Location

264 Mesogion Avenue, Athens, Attica, Greece

Site insights

Top conditions

Top treatments

Ifinatamab Deruxtecan

5-Fluorouracil

MK-1084

Palbociclib

Modufolin

Gedatolisib

Abiraterone Acetate

MK-1084-007

Irinotecan

PF-06821497

Parent organization

This site is a part of Metropolitan General Hospital

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 12 total trials

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

Researchers want to learn if the study medicines calderasib and subcutaneous (SC) pembrolizumab can be used to treat non-small cell lung cancer (NSCL...

Enrolling

Non-small Cell Lung Cancer

Drug: Carboplatin

Drug: Calderasib

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine cal...

Enrolling

Prostatic Neoplasms

Prostate Cancer

Drug: Prednisone

Drug: Ifinatamab deruxtecan

A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)

Researchers are looking for new ways to treat people with high-risk non-muscle invasive bladder cancer (HR NMIBC). NMIBC is cancer in the tissue that...

Enrolling

Urinary Bladder Neoplasms

Carcinoma in Situ

Biological: Intismeran autogene

Biological: BCG

A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).

Pfizer MEVPRO-1 (C2321014) is a randomized, open-label, multi-center clinical trial evaluating whether combining the study medicine (PF-06821497) wit...

Enrolling

Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Drug: PF-06821497

Drug: Enzalutamide

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

This is a Phase 3 Randomized, double-blind, Multiregional Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemothe...

Enrolling

Non-Small Cell Lung Cancer

Biological: Ivonescimab Injection

Biological: Pembrolizumab Injection

Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)

This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbocic...

Active, not recruiting

Breast Cancer

Drug: Alpelisib

Drug: Fulvestrant

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1. (Be6A Lung-02)

The purpose of the study is to compare how the new combination treatment (Sigvotatug Vedotin plus pembrolizumab) works compared to pembrolizumab alon...

Enrolling

Carcinoma, Non-Small-Cell Lung (NSCLC)

Carcinoma, Non-Small-Cell Lung

Drug: Pembrolizumab

Drug: Sigvotatug Vedotin